New hope for rare blood cancer: drug combo targets relapsed lymphoma
NCT ID NCT05700448
First seen Feb 05, 2026 · Last updated May 09, 2026 · Updated 12 times
Summary
This study tests whether adding the drug sugemalimab to standard chemotherapy can help people with a rare type of blood cancer (extranodal NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 adults will receive either the combination or a placebo plus chemo. The main goal is to see if the new combination delays cancer growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.